A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.

Winkelman, John W.; Schoerning, Laura; Platt, Samuel; Mei, Leslie A; Mackie, Susan E

doi:10.1016/j.sleep.2016.05.004

Work

A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.

Público Deposited

MLA citation style (9th ed.)

Winkelman, John W, et al. A Method to Switch From Oral Dopamine Agonists to Rotigotine In Patients with Restless Legs Syndrome and Mild Augmentation. . 8120. mushare.marian.edu/concern/generic_works/3abe6bce-0b04-4aba-9d45-0f52c2ea389c?locale=es.

APA citation style (7th ed.)

W. J. W, S. Laura, P. Samuel, M. L. A, & M. S. E. (8120). A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. https://mushare.marian.edu/concern/generic_works/3abe6bce-0b04-4aba-9d45-0f52c2ea389c?locale=es

Chicago citation style (CMOS 17, author-date)

Winkelman, John W., Schoerning, Laura, Platt, Samuel, Mei, Leslie A, and Mackie, Susan E. A Method to Switch From Oral Dopamine Agonists to Rotigotine In Patients with Restless Legs Syndrome and Mild Augmentation. 8120. https://mushare.marian.edu/concern/generic_works/3abe6bce-0b04-4aba-9d45-0f52c2ea389c?locale=es.

Note: These citations are programmatically generated and may be incomplete.

BACKGROUND: We examined the short- and long-term efficacy and tolerability of a cross-titration algorithm from oral dopamine agonists to the rotigotine transdermal patch in patients dissatisfied with their restless legs syndrome (RLS) treatment, predominantly with mild augmentation. METHODS: Patients with RLS (n?=?20) were recruited at a single site. The cross-titration consisted of decreasing oral dopaminergic agents (ropinirole by 1?mg or pramipexole by 0.25?mg) and increasing rotigotine by 1?mg every two days. Efficacy and adverse events (AEs) were assessed at one, three, six and 12 months after the switch. RESULTS: Patients had moderate-severe RLS symptoms at the baseline (mean international restless legs syndrome (IRLS) score 19.4?±?5.5); 85% had augmentation and 45% reported afternoon RLS symptoms. The baseline mean pramipexole equivalent dose was 0.6?±?0.3?mg. At Week 5, 85% (17/20) had successfully switched from their oral dopamine agonist to rotigotine (mean dose 2.5?±?0.6?mg; change in IRLS score: -6.7?±?8.4, p?=?0.002); 14 patients were CGI-I responders (much or very much improved). Three patients withdrew due to lack of efficacy. Twelve months after cross-titration, 10 patients continued on rotigotine, of whom four required either higher doses of rotigotine or supplemental RLS medication compared with their optimal Week 5 dose; five patients withdrew due to AEs and two due to lack of efficacy. CONCLUSION: A cross-titration to rotigotine was efficacious after five weeks in 70% of patients dissatisfied with RLS treatment, most of whom had mild augmentation. At one year following the medication switch, 50% had discontinued rotigotine due to lack of continued efficacy or side effects.

Creator

Language